

FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES **(or securities convertible or exchangeable into listed securities)**

Please complete the following:

Name of CSE Issuer: Lexaria Bioscience Corp.

Trading Symbol: LXX

Date: January 17, 2018

Is this an updating or amending Notice: Yes X No

If yes provide date(s) of prior Notices:

Issued and Outstanding Securities of Issuer Prior to Issuance: 70,319,707

Date of News Release Announcing Private Placement:

Closing Market Price on Day Preceding the Issuance of the News Release:

CAD\$2.20 and US\$1.82

- 1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)**

Full Name & Residential Address of Place	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Investor Company ITF Anson Investments Master Fund LP A/C 5J5636F C/O TD Waterhouse 77 Bloor St West, 3 rd Floor Toronto, ON M5S 1M2	476,500 common shares for warrant exercise	US\$0.60				January 17, 2018	NOT Related. Third party.
Haywood Securities Inc 700-200 Burrard St Vancouver, BC V6C 3L6	59,300 common shares for warrant exercise	US\$0.60				January 17, 2018	NOT Related. Third party.
Haywood Securities Inc 700-200 Burrard St Vancouver, BC V6C 3L6	6,532 common shares for warrant exercise	US\$0.42				January 17, 2018	NOT Related. Third party.
JGRNT Capital Corp 1 Scott St. #402 Toronto, Ontario M5E 1A1	500,000 warrants expiring Jan 17, 2020 each warrant valid to buy one common share at US\$1.83	US\$1.83				Issued as per Consulting Agreement	NOT Related. Third party consultant

Haywood Securities Inc 700-200 Burrard St Vancouver, BC V6C 3L6	3,266 compensation warrants expiring Apr 3, 2019. Each warrant valid to buy one common share at US\$0.60.	US\$0.60				Issued as per April 3 2017 Private Placement contract	NOT Related. Third party
Canaccord Genuity ITF Ron Struthers A/C 17H-137A-5 2200-609 Granville St Vancouver, BC V7Y 1H2	110,000 common Share issuance due to exercise of stock options	\$US0.2273				January 17, 2018	NOT Related. Third party

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.

(2) Indicate if Related Person.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: **Raised USD \$349,223.44 . If all 503,266 new warrants are eventually exercised then the total amount of additional new funds to be raised would be \$916,959.60**

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

Not Applicable

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer:

Not Applicable

4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.

Not Applicable

5. Description of securities to be issued:

- (a) Class **common shares**
- (b) Number **652,332**
- (c) Price per security **535,800 @ US\$0.60 and 6,532 @ US\$0.42 and 110,000 @ US\$0.2273**
- (d) Voting rights _____

6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:

- (a) Number **503,266**
- (b) Number of securities eligible to be purchased on exercise of Warrants (or options) **503,266**
- (c) Exercise price **500,000 @ US\$1.83 and 3,266 @ US0.60**
- (d) Expiry date: **January 17, 2020 and April 3, 2019**

7. Provide the following information if debt securities are to be issued:

- (a) Aggregate principal amount **N/A**
- (b) Maturity date **N/A**
- (c) Interest rate **N/A**
- (d) Conversion terms

- (e) Default provisions

Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.): **Not applicable**

8. (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):

Not applicable

- (b) Cash _____ .
- (c) Securities _____ .
- (d) Other _____ .
- (e) Expiry date of any options, warrants etc.
- (f) Exercise price of any options, warrants etc. _____ .

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship _____

Not applicable.

10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).

Not applicable.

11. State whether the private placement will result in a change of control.

Not applicable.

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders.

Not applicable

_____ .

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by Multilateral Instrument 45-102.

2. Acquisition

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:
Not applicable.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: __
Not applicable

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments: **Not applicable**
 - (a) Total aggregate consideration in Canadian dollars: _____ .
 - (b) Cash: _____ .
 - (c) Securities (including options, warrants etc.) and dollar value: _____ .
 - (d) Other: _____ .
 - (e) Expiry date of options, warrants, etc. if any: _____ .
 - (f) Exercise price of options, warrants, etc. if any: _____ .
 - (g) Work commitments: _____ .

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).
Not applicable

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: _____
Not applicable

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows: **Not applicable**

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: _____
Not applicable
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.): **Not applicable**
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____
- (b) Cash _____ .
- (c) Securities _____ .
- (d) Other _____ .
- (e) Expiry date of any options, warrants etc. _____
- (f) Exercise price of any options, warrants etc. _____ .
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship.
Not applicable
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months.

Not applicable

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 9 Notice of Private Placement is true.

Dated January 17, 2018

Christopher Bunka
Name of Director or Senior
Officer

"Christopher Bunka"
Signature

Chairman/CEO
Official Capacity